Two Sigma Advisers LP Makes New $2.39 Million Investment in Haleon plc (NYSE:HLN)

Two Sigma Advisers LP bought a new position in Haleon plc (NYSE:HLN - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 250,600 shares of the company's stock, valued at approximately $2,391,000.

Several other large investors have also recently modified their holdings of HLN. Sierra Ocean LLC purchased a new position in shares of Haleon in the fourth quarter worth about $26,000. Geneos Wealth Management Inc. bought a new stake in Haleon during the 4th quarter worth approximately $35,000. Spire Wealth Management bought a new stake in Haleon during the 4th quarter worth approximately $39,000. FIL Ltd increased its holdings in Haleon by 45.7% during the 4th quarter. FIL Ltd now owns 4,049 shares of the company's stock worth $39,000 after acquiring an additional 1,270 shares during the period. Finally, Addison Advisors LLC increased its holdings in Haleon by 28.7% during the 4th quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock worth $47,000 after acquiring an additional 1,106 shares during the period. Hedge funds and other institutional investors own 6.67% of the company's stock.

Haleon Price Performance

HLN stock traded up $0.07 during midday trading on Monday, reaching $11.42. The company had a trading volume of 14,848,126 shares, compared to its average volume of 8,533,273. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. Haleon plc has a 1 year low of $8.25 and a 1 year high of $11.42. The company has a market capitalization of $51.42 billion, a P/E ratio of 33.57, a P/E/G ratio of 2.82 and a beta of 0.24. The firm has a 50-day moving average price of $10.43 and a 200-day moving average price of $9.99.

Haleon (NYSE:HLN - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The business had revenue of $3.54 billion during the quarter, compared to analysts' expectations of $3.38 billion. On average, research analysts anticipate that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HLN has been the topic of a number of analyst reports. BNP Paribas Exane raised shares of Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 target price on the stock in a report on Tuesday, May 27th. Morgan Stanley raised shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 target price on the stock in a report on Friday, May 9th. HSBC reaffirmed a "hold" rating on shares of Haleon in a report on Wednesday, March 5th. Barclays reaffirmed an "overweight" rating on shares of Haleon in a report on Tuesday, May 6th. Finally, Wall Street Zen lowered shares of Haleon from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Six analysts have rated the stock with a hold rating, four have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Haleon presently has a consensus rating of "Moderate Buy" and a consensus target price of $12.33.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.